Medication-Assisted Treatment (MAT) combines FDA-approved medications with counseling and behavioral therapies to treat substance use disorders, with particular effectiveness for opioid use disorder (OUD). It addresses both the physical aspects of addiction — including withdrawal symptoms and persistent cravings — and the psychological factors that drive continued substance use. By stabilizing these symptoms with evidence-based medication, individuals are better positioned to engage meaningfully in therapy and rebuild their daily lives.
This article explains what MAT is, its measurable benefits, the medications used, and how enrollment works at structured programs such as Huntington Addiction Wellness Center (HAWC Recovery), a CARF-accredited treatment provider in Huntington, West Virginia.
What Is Medication-Assisted Treatment and How Does It Support Addiction Recovery?
MAT is a coordinated treatment approach that pairs carefully selected medication with counseling and behavioral support. For opioid use disorder specifically, medications reduce the severity of withdrawal and cravings, allowing individuals to participate more fully in the therapeutic work that underpins lasting recovery. Treating both the body and the mind — simultaneously — produces a more complete and durable path forward.
At HAWC Recovery, the clinical team delivers a structured, long-term program that integrates medical monitoring with individual and group therapy. Founded in 2020 and holding both WVARR and CARF accreditations, HAWC has developed an approach that recognizes the diverse pathways people take into recovery. You can learn more about how their program is structured by visiting their three-phase program overview.
How Does MAT Combine Medication and Therapy?
MAT uses medication to stabilize brain chemistry and reduce the physical symptoms of dependence, while therapy simultaneously addresses behavior patterns, relapse triggers, and coping strategies. The three medications most commonly used — buprenorphine, methadone, and naltrexone — each work differently to control physical symptoms, freeing the person to engage more deeply in the recovery process.
Therapeutic elements such as individual counseling, group sessions, and approaches like Cognitive Behavioral Therapy (CBT) teach practical skills for managing stress, identifying and avoiding triggers, and building sustainable healthy routines. Medication and therapy reinforce one another: the medication creates the biological stability for therapy to take hold, while therapy builds the behavioral tools needed to maintain that stability over time.
It is also worth noting that many individuals seeking MAT may be managing co-occurring mental health conditions — such as anxiety, depression, or PTSD — alongside their substance use disorder. Experienced providers recognize that effective treatment must be attentive to both dimensions from the outset.
What Are the Measurable Benefits of MAT for Long-Term Stability?
Research consistently shows that MAT produces meaningful improvements in stability and daily functioning compared with no treatment or behavioral therapy alone. According to SAMHSA, MAT has been shown to improve patient survival, increase treatment retention, and reduce illicit drug use and associated criminal activity.
Common practical advantages include:
- Structured Daily Routine: Regular appointments for medication management and therapy help individuals establish consistency, which itself is protective against relapse.
- Biopsychosocial Assessment: Comprehensive evaluations conducted at admission identify any co-occurring mental health needs, ensuring that the full picture of a person’s wellbeing is addressed, not just the addiction.
- Vocational Training and Employment Support: Many structured MAT programs provide resources for job training and employment assistance, helping individuals rebuild their role in the workforce and in their communities.
- Community Support and Housing Assistance: Access to recovery housing and community resources can significantly improve an individual’s ability to maintain sobriety and build long-term stability.
| Benefit | Description | Impact Level |
| Structured Daily Routine | Regular appointments help establish consistency | High |
| Biopsychosocial Evaluation | Identifies co-occurring mental health needs alongside addiction | High |
| Vocational Training | Supports reintegration into the workforce | Medium |
| Community Support | Provides resources for housing and social connections | High |
The combination of regular clinical oversight, trained staff, and structured routines in MAT programs creates a safer, more supported environment for recovery — and substantially reduces the likelihood of relapse.
Which Medications Are Used in MAT Programs?
MAT uses three primary FDA-approved medications for opioid use disorder. Each has a distinct mechanism of action, and clinicians select among them based on each person’s medical history, level of dependence, and treatment goals:
- Buprenorphine: A partial opioid agonist that reduces cravings and eases withdrawal symptoms without producing the full euphoric effect of opioids.
- Methadone: A long-acting full opioid agonist that stabilizes individuals by maintaining consistent medication levels, reducing cravings and withdrawal.
- Naltrexone: An opioid antagonist that blocks opioid receptors entirely, removing the rewarding effects of opioids and helping prevent relapse.
Individualized medication selection — guided by a thorough clinical evaluation — is central to effective MAT. There is no single best option; the right choice depends on the individual.
The Role of Each Medication in Treatment
Buprenorphine
Buprenorphine is a Schedule III partial opioid agonist with high binding affinity for the mu-opioid receptor. Unlike full agonists, its partial activation profile means it alleviates withdrawal and cravings while substantially limiting the risk of euphoria and respiratory depression — a significant safety advantage. It is frequently prescribed in combination with naloxone (as Suboxone) to deter misuse.
Typical starting doses fall in the range of 4 to 24 mg per day, with adjustments made based on clinical response during regular follow-up visits. Buprenorphine can be prescribed in outpatient settings, increasing accessibility and allowing care to fit within a person’s existing routine.
“Buprenorphine is a Schedule III opioid analgesic with unique pharmacodynamic and pharmacokinetic properties… Buprenorphine may have a unique role in mediating analgesic signaling at spinal opioid receptors while having less of an effect on brain receptors, potentially limiting classic opioid-related adverse events such as euphoria, addiction, or respiratory depression.” — A narrative pharmacological review of buprenorphine: a unique opioid for the treatment of chronic pain, 2020
Methadone
As a long-acting full mu-opioid receptor agonist, methadone provides stable, continuous medication levels that suppress withdrawal and cravings for 24 to 36 hours per dose. It is typically dispensed through federally regulated opioid treatment programs (OTPs), where clinical staff can supervise dosing and monitor safety. This controlled setting is especially important for individuals with moderate to severe opioid dependence.
“Methadone maintenance treatment (MMT) is a long-term opioid replacement therapy, effective in the management of opioid dependence.” — Methadone maintenance at different dosages for opioid dependence, F. Faggiano, 1996
Naltrexone
Naltrexone is a potent antagonist at mu-opioid receptors and a weaker antagonist at kappa- and delta-receptors. By blocking these receptors, it renders opioids unable to produce their rewarding effects — removing a key driver of relapse. It is most suitable after a person has completed detoxification, as it can precipitate withdrawal if opioids are still present in the system.
Naltrexone is available as a daily oral tablet or as an extended-release monthly injection (Vivitrol), FDA-approved for opioid dependence in 2010. The injectable formulation improves adherence by eliminating the need for daily dosing decisions. Clinical studies consistently support its effectiveness when used as part of a comprehensive recovery plan that includes counseling.
“Naltrexone is a relatively weak antagonist of kappa- and delta-receptors and is also a potent mu-receptor antagonist. Dosages of naltrexone that effectively reduce opioid and alcohol consumption also actively block mu-receptors.” — Analysis of evidence for the combination of pro-dopamine regulator (KB220PAM) and naltrexone to prevent opioid use disorder relapse, E.J. Modestino, 2018
Common Side Effects and Safety Considerations
All MAT medications are clinically effective but carry potential side effects that require monitoring:
- Buprenorphine: Headache, nausea, constipation, and sweating. Risk of misuse is reduced but not eliminated, particularly without the naloxone combination.
- Methadone: Drowsiness, sweating, constipation, and a risk of cardiac arrhythmia (QTc prolongation) at higher doses. Overdose risk is meaningful if misused or combined with other CNS depressants; regular clinical monitoring is essential.
- Naltrexone: Nausea, headache, fatigue, and, in some cases, liver enzyme elevations at high doses. A baseline liver function assessment is recommended prior to initiation.
Safe MAT delivery requires regular check-ins, dose adjustments based on clinical response, patient education, and vigilant monitoring for drug interactions and signs of misuse. Providers also screen for co-occurring mental health conditions — such as depression, anxiety, or trauma — that may affect medication response and overall treatment needs.
Treatment Duration and Patient Eligibility
There is no single correct duration for MAT. The most current clinical guidance from SAMHSA and the American Society of Addiction Medicine (ASAM) supports indefinite maintenance treatment for many patients, similar to the long-term management of other chronic conditions. Some individuals use medication for several months; others continue for years or indefinitely. Decisions about tapering or discontinuing medication should be made collaboratively, based on clinical stability and the individual’s goals.
Eligibility for MAT generally requires a confirmed diagnosis of opioid use disorder and a commitment to engaging in counseling alongside medication. A comprehensive clinical evaluation — which may include a biopsychosocial assessment to identify any co-occurring psychiatric conditions — guides the selection of medication and the structure of the overall care plan.
How HAWC Recovery Supports Opioid Use Disorder Treatment
HAWC Recovery takes a long-term, structured approach to opioid use disorder treatment that goes well beyond short-term stabilization. Clients begin Phase 1 (inpatient treatment) with a full medical physical, a biopsychosocial evaluation — which screens for co-occurring mental health conditions — and weekly doctor visits throughout their stay. Clinical therapy includes both individual and group sessions, with evidence-based approaches such as CBT and Contingency Management.
What distinguishes HAWC’s model is its three-phase continuum of care. Phase 1 stabilizes the individual medically and emotionally. Phase 2 provides structured sober living alongside job placement — every client secures employment before leaving inpatient care. Phase 3 offers low-cost graduate housing with continued outpatient therapy, helping clients build savings and independence while remaining connected to clinical support. This extended structure significantly reduces relapse risk in the critical months following early recovery.
For individuals whose clinical picture includes co-occurring mental health challenges — a common reality in opioid use disorder — HAWC’s biopsychosocial evaluation and individualized care planning ensure that those needs are identified and addressed as part of the broader recovery journey.
HAWC serves primarily individuals in West Virginia and within a 50-mile radius. They accept all West Virginia Medicaid plans, PEIA, and Blue Cross Blue Shield / Highmark, and can often assist with presumptive Medicaid enrollment for those currently uninsured.
Enrollment and Pre-Assessment at HAWC Recovery
The enrollment process at HAWC Recovery is designed to be clear, confidential, and low-barrier. It follows three key steps:
- Confidential Pre-Assessment: Prospective clients complete a private assessment covering substance use history, medical background, and personal goals. This determines program fit and guides the recommended care pathway.
- Clinical Review and Planning: HAWC’s clinical team reviews the assessment findings, discusses appropriate treatment options, and explains the three-phase program structure. Individuals are given the information they need to make an informed decision about their recovery.
- Admission Scheduling: Once a plan is established, the team assists with scheduling admission to Phase 1 inpatient treatment, including insurance verification and any necessary coordination for medical detox if required prior to admission.
To take the first step, you can begin with a confidential pre-assessment at HAWC Recovery. Their team is available to answer questions and guide you through the process.
Frequently Asked Questions
MAT adds FDA-approved medication to the counseling and behavioral therapies that form the core of traditional addiction treatment. The medication manages the physiological symptoms of dependence — withdrawal and cravings — so that individuals can engage more effectively in therapy. Research consistently shows that combined approaches produce better treatment retention and long-term outcomes than behavioral therapy alone.
Eligibility generally requires a confirmed diagnosis of opioid use disorder and a willingness to participate in counseling alongside medication. Clinicians assess medical history, substance use patterns, the presence of any co-occurring mental health conditions, and personal circumstances to determine whether MAT is appropriate and, if so, which medication best fits the individual’s needs.
MAT duration varies considerably by individual. Current clinical guidelines support long-term maintenance for many patients, as opioid use disorder is a chronic condition that benefits from sustained medical support. Regular clinical reviews guide decisions about continuing, adjusting, or tapering medication based on recovery progress and the individual’s goals.
Yes — MAT is most effective when integrated with counseling, behavioral therapies, support groups, and structured programming. Addressing the biological, psychological, and social dimensions of addiction together produces the most durable outcomes. For individuals with co-occurring mental health conditions, integrated dual-diagnosis care further improves the chances of sustained recovery.
Initial assessments are confidential and typically cover substance use history, medical and psychiatric background, and social circumstances. The goal is to understand the full picture — including any mental health conditions that co-occur with addiction — and to identify the most appropriate medication, therapeutic approach, and level of care for each individual.
Yes. Clinicians commonly recommend a balanced diet, regular physical activity, a consistent daily routine, and avoiding alcohol and illicit substances. Building a support network through therapy, peer recovery groups, and community resources is also strongly encouraged. These lifestyle elements work in concert with medication to support lasting recovery and overall wellbeing.
This article is intended for informational purposes only and does not constitute medical advice. If you or a loved one is struggling with opioid use disorder, please consult a qualified healthcare professional or contact HAWC Recovery at (681) 204-5400 for a confidential assessment.
